Tag: Regulatory scrutiny

Compared to other medications for similar conditions, the use of semaglutide medications—Ozempic for type 2 diabetes and Wegovy for weight loss—is not linked to an increased risk of suicidal ideation, according to a comprehensive review of U.S. health records funded by the National Institutes of Health. Consoling Outcomes Despite Regulatory Review This analysis dispels worries…